Table 2 Demographic characteristics and co-morbidities of people with complete heart block
Patient Characteristics | n (%) (N = 7) | p-value* |
|---|---|---|
Sex (male) | 3 (42.86%) | 0.143 |
Age | (median79) | 0.241 |
Medical comorbidities | ||
Diabetes | 1 (14.29%) | 1.00 |
Hypertension | 6 (85.71%) | 1.00 |
Coronary artery disease | 1 (14.29%) | 1.00 |
COPD | 1 (14.29%) | 1.00 |
Obstructive sleep apnea | 2 (28.57%) | 1.00 |
Stroke or TIA | 1 (14.29%) | 1.00 |
Prior or current smoker | 3 (42.86%) | 1.00 |
Prior pericarditis | 0 (0%) | |
Heart failure | 0 (0%) | |
Atrial fibrillation | 1 (14.29%) | 0.286 |
Hyperlipidemia | 5 (71.43%) | 1.00 |
Medications | ||
Antihypertensive | 4 (57.14%) | |
Antiplatelet | 2 (28.57%) | |
Anticoagulant | 3 (42.86%) | |
Atrioventricular node blocking agent | 1 (14.29%) | |
Cancer primary | ||
Lung adenocarcinoma | 2 (28.57%) | |
Renal cell carcinoma | 1(14.29%) | |
Vaginal melanoma | 1(14.29%) | |
Bladder urothelial squamous carcinoma | 1(14.29%) | |
Renal clear cell carcinoma | 1(14.29%) | |
Testicular sertoli cell carcinoma | 1 (14.29%) | |
Stage at initiation of ICI therapy | ||
Stage IIIb | 1 (14.29%) | |
Stage IV | 6 (85.71%) | |
Systemic anti cancer treatments | ||
Durvalumab | 1 (14.29%) | |
Intravesical mitomycin C | 1 (14.29%) | |
Carboplatin & Paclitaxal | 1 (14.29%) | |
Carboplatin & Pemetrexed | 1 (14.29%) | |
Durvalumab | 1 (14.29%) | |
Axitinib | 1 (14.29%) | |
Cabozantanib | 1 (14.29%) | |
Radiation therapy | 4 (57.14%) | |